scm logo

As promised at the 8th regular general meeting of shareholders,

we would like to inform you of the results of the R&D open innovation seminar held by SCM Lifescience, Inc.

On April 26, SCM Lifescience, Inc. invited Jong-Su Lee, Chairman of The Korean Ophthalmological Society (Professor, Pusan National University College of Medicine)

to hold an R&D Open Innovation seminar under the theme of ‘Applied corneal treatment using corneal tissue cells’.

This seminar, which was held face-to-face for the first time since COVID-19, was hosted by the Research & Business Innovative Development Division

(hereinafter referred to as the Innovation Headquarters). The seminar covered the types of corneal transplantation and research trends on corneal treatment including transplantation surgery methods.

Although corneal transplantation is the best effective treatment method for corneal damage-related diseases caused by aging, trauma, inflammation, and indiscriminate contact lens wear,

the demand for donor corneas has decreased due to the continuous increase in global demand for corneal transplantation and the aging of corneal donors.

The fact that there was a serious imbalance in supply was discussed as a big problem.

Through this seminar,

Chairman Lee Jong-soo stressed that if SCM Lifescience, Inc. actively utilizes high-purity and high-efficiency stem cells, effective treatments can be found,

and stem cells will be a good therapeutic approach to various eye diseases accompanied by corneal damage.

He also mentioned that if strategic collaboration between SCM Life science Inc. and clinical researchers of the Korean Academy of Ophthalmology is achieved through R&D open innovation,

it can become a good example of open innovation in the field of corneal treatment.

Through open innovation with the Korean Academy of Ophthalmology, the Innovation Headquarters of SCM Life Sciences, which is exploring new indications,

found that non-clinical cell and animal tests for corneal diseases can obtain reliable data faster than other diseases. and It also highly evaluated that it could find a connection to the open innovation with the University of Utah, which is currently in progress.

Through this R&D Open Innovation Seminar of The Korean Ophthalmological Society,

It is expected that high-purity, high-potency stem cells cultured with SCM Life Science's proprietary isolation and source technology will be of great help to the market for corneal transplantation and corneal disease treatment, which is in increasing demand at this time.